Preferential usage of T cell receptor (TCR) Vβ by allogeneic T cells recognizing myeloid leukemia cells: Implications for separating graft-versus-leukemia effect from graft-versus-host disease

Bone Marrow Transplantation

Volumn 19, Issue 9, 1997, Pages 899-903

  Jiang, Y Z ^a,b   Mavroudis, D A ^a   Dermime, S ^a   Molldrem, J ^a   Hensel, N F ^a   Barrett, A J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

BMT; CML; GVHD; GVL; mHA; TCR

Indexed keywords

PHYTOHEMAGGLUTININ; RECEPTOR ANTIBODY; T LYMPHOCYTE RECEPTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CELL STIMULATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DONOR; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKEMIA CELL; LYMPHOBLAST; LYMPHOCYTE CLONE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; SIBLING; T LYMPHOCYTE; TRANSFUSION;

EID: 0030917167     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700769     Document Type: Article

References (21)

1. Barrett AJ, Malkovska V. Review. Graft-versus-leukemia: understanding and using the alloimmune response to treat hematological malignancies. Br J Haematol 1996; 93: 754-761.
2. Beatty PG, Anasetti C, Hansen JA et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993; 81: 249-253.
3. Van Lochem E, de Gast B, Goulmy E. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 1992; 10: 181-183.
4. Weiden PL, Flournoy N, Thomas ED et al. Antileukemia effect of graft versus host disease in human recipients of allogeneic marrow graft. New Engl J Med 1979; 300: 1068-1073.
5. Van Rhee F, Kolb H-J. Donor leukocyte transfusions for leukemic relapse. Curr Opin Hematol 1995; 2: 423-430.
6. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
7. van der Harst D, Goulmy E, Falkenburg JHF et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 1994; 83: 1060-1066.
8. Liu X, Chesnokova V, Forma SJ, Diamond DJ. Molecular analysis of T-cell receptor repertoire in bone marrow transplant recipients: evidence for oligoclonal T-cell expansion in graft-versus-host disease lesions. Blood 1996; 87: 3032-3044.
9. Kubo K, Yamanaka K, Kiyoi H et al. Different T-cell receptor repertoires between lesions and peripheral blood in acute graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1996; 87: 3019-3026.
10. Howell CD, Li J, Roper E, Kotzin BL. Biased liver T cell receptor Vβ repertoire in a murine graft-versus-host disease model. J Immunol 1995; 155: 2350-2358.
11. Datta AR, Barrett AJ, Jiang YZ et al. Distinct T cell populations distinguish chronic myeloid leukemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant 1994; 14: 517-524.
12. Marrack P, Kappler J. T cells can distinguish between allogeneic major histocompatibility complex products on different cell types. Nature 1988; 332: 840-843.
13. Jiang YZ, Barrett AJ. Cellular and cytokine mediated effects of CD4+ lymphocyte lines generated in vitro against chronic myelogenous leukemia. Exp Hematol 1995; 23: 1167-1172.
14. Jiang YZ, Mavroudis DA, Dermime S et al. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to CML cells processing and presenting exogenous antigen. Br J Haematol 1996; 93: 606-612.
15. Nimer SD, Giorgi J, Gajewski JL et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. Transplantation 1994; 57: 82-87.
16. Herrera C, Martin C, Garcia-Castellano JM et al. Prevention of GVHD by selective CD4+ T cell depletion plus adjustment of the CD8+ cell content in donor bone marrow. Blood 1995; 86 (Suppl. 1): 571a (Abstr.).
17. Mackinnon S, Papadoponlos EB, Carabsi M et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of CML after bone marrow transplantation: separation of graft versus leukemia responses from graft versus host disease. Blood 1995; 86: 1261-1268.
18. Barrett AJ, Couriel D, Dunbar CE et al. Low incidence of acute GVHD following delayed T-cell add-back after T-depleted BMT for hematologic malignancies. Blood 1995; 86 (Suppl. 1): 619a (Abstr.).
19. Berenson RJ, Andrews RG, Bensinger WI et al. Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest 1988; 81: 951-955.
20. Kato K, Radbruch A. Isolation and characterization of CD34+ hematopoietic stem cells from human peripheral blood by high-gradient magnetic cell sorting. Cytometry 1993; 14: 384-392.
21. Pati AR, Godder K, Abhyankar S et al. Pre-emptive donor leukocyte infusion to prevent relapse in patient with high risk hematological malignancies undergoing bone marrow transplant using partially mismatched related donors. Blood 1995; 86 (Suppl. 1): 564a (Abstr.).